The Centers for Medicare and Medicaid Services has created a system in which Wall Street actors and insurance conglomerates have extracted large profits at the expense of Medicare, its patients and taxpayers – according to a new report co-authored by a Cornell professor.
Only one in five Medicaid enrollees diagnosed with hepatitis C virus started treatment, according to a retrospective study led by researchers at Weill Cornell Medicine and Cornell University’s Ithaca campus.
The Sloan Program in Health Administration in the Cornell Jeb E. Brooks School of Public Policy has once again been ranked among the best in the nation. The new U.S. News rankings have the program rising to the No. 8 spot.
A preclinical study has shown that colorectal pre-cancerous lesions known as serrated polyps, and the aggressive tumors that develop from them, depend on the ramped-up production of cholesterol, which points to the possibility of using cholesterol-lowering drugs to prevent or treat such tumors.
Victoria Bent MHA '23 is one of the organizers of the Women+ in Health Care Leadership Symposium. The event is sponsored by the Sloan Program in Health Administration in the Cornell Jeb E. Brooks School of Public Policy and it will focus on personal development skills.
Weill Cornell Medicine associate professor Gregory F. Sonnenberg has been awarded a five-year, $3.26 million grant from the National Institutes of Health to investigate the underlying mechanisms of inflammatory bowel disease.
An interdisciplinary collaboration used a cutting-edge form of RNA tagging to map the gene expression that occurs during follicle maturation and ovulation in mice, an approach that could lead to therapeutic treatments for infertility.
During the COVID-19 pandemic, many U.S. hospitals had overcapacity intensive care units while other area hospitals had open ICU beds available, a phenomenon known as “load imbalance.”
In experiments of unprecedented scale, researchers at Weill Cornell Medicine and the NIH have advanced efforts to better understand and ultimately treat this common metabolic disease.
Removing race information from cardiovascular risk calculators – which predict the probability of developing heart disease – doesn’t affect patients’ risk scores, according to a study by Weill Cornell Medicine and NewYork-Presbyterian investigators.